Release Date: March 12, 2025
Expiration Date: March 12, 2026
Activity Overview
Sickle cell disease (SCD) is a continually increasing health problem on a global scale. Fortunately, clinical outcomes have improved over the years, namely through the development of disease-modifying therapies, curative approaches, and improvements in supportive care.
This activity provides clinicians with different perspectives on therapeutic strategies for patients with SCD, including disease modifying therapy and curative therapy and the relative risks and benefits of hematopoietic stem cell transplantation and gene therapy. Through education, clinicians will be better placed to help improve outcomes and quality of life for their patients with SCD.
Target Audience
This activity is directed towards hematologists. Primary care providers, specialty NPs, PAs, RNs, and other providers involved in the sickle cell disease care team may also find it useful.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical trial data for approved therapies in SCD
- Review factors that impact treatment selection for patients with SCD
- Design individualized multidisciplinary care plans for patients with SCD
Biree Andemariam, MD
Professor of Medicine
Founding Director, New England Sickle Cell Institute
University of Connecticut Health Center
Director, Connecticut Bleeding Disorders Center
Farmington, CT
Disclosures: Grant/Research Support: Afimmune, Agios Pharmaceuticals, Novo Nordisk, Pfizer; Consultant: Afimmune, Agios Pharmaceuticals, Bluebird Bio, Novo Nordisk, Pfizer, Roche, Sanofi Genzyme, Vertex Pharmaceuticals.
Matthew M. Heeney, MD
Associate Chief - Hematology
Division of Hematology/Oncology
Boston Children's Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, MA
Disclosures: Consultant: Beam Therapeutics, Bluebird Bio, Blueprint Medicine, Novartis, Omeros, Pfizer, Sanofi, Weatherden; Researcher: Beam Therapeutics, Novartis.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
